Skip to main content

Table 2 Performance of previously published protein prognostic biomarker candidates in OSskcm

From: OSskcm: an online survival analysis webserver for skin cutaneous melanoma based on 1085 transcriptomic profiles

Gene symbol Literature data Validation results
References n Survival endpoint Prognostic significance of high expression HR (95%CI) Log-rank P value Datasets Cut off
KLK7 [20] 45 OS Good 2.65 (1.27–5.53)† 0.0095 GSE17275 Upper 25%
      3.60 (1.48–8.80)† 0.0049 GSE19234 Upper 25%
      1.93 (1.40–2.65)† < 0.0001 TCGA Upper 25%
MITF [29] 200 OS Poor 1.43 (1.09–1.87)† 0.0104 TCGA Upper 50%
      3.46 (1.42–8.42)† 0.0063 GSE19234 Upper 50%
      3.33 (1.18–9.41)† 0.0230 GSE98394 Upper 50%
KIF20A [30] 61 RFS Poor 2.17 (1.12–4.20)† 0.0218 GSE22155 Upper 25%
      2.56 (1.20–5.47)† 0.0151 GSE50509 Upper 25%
      3.21 (1.26–8.20)† 0.0147 GSE98394 Upper 25%
      2.44 (1.02–5.83)† 0.0454 GSE19234 Upper 25%
CTHRC1 [31] 35 OS Poor 3.41 (1.31–8.89)† 0.0122 GSE98394 Upper 25%
TFAP2A [32] Nearly 600 DSS Poor 1.59 (1.03–2.47)‡ 0.0379 GSE65904 Upper 25%
ATF2 [33] 544 OS Poor 3.05 (1.56–5.97)† 0.0012 GSE22155 Upper 25%
NCOA3 [34] 343 RFS and DSS Poor 1.79 (1.17–2.74)‡ 0.0071 GSE65904 Upper 25%
BCL2 [35] 339 OS Good 0.21 (0.04–0.97)† 0.0458 GSE22155 Upper 25%
BIRC5 [36] 50 DFS and OS Poor 3.73 (1.44–9.67)† 0.0068 GSE98394 Upper 25%
MCAM [37] 76 OS Poor 4.66 (1.78–12.18)† 0.0017 GSE19234 Upper 25%
PLAT [38] 214 DMFI and OS Poor 2.24 (1.16–4.34)† 0.0164 GSE22155 Upper 25%
      3.88 (1.47–10.24)† 0.0063 GSE98394 Upper 25%
NOS2 [39] 132 DSS and OS Poor 1.41 (1.07–1.85)† 0.0131 TCGA Upper 50%
CDKN1B [40] 383 DSS and OS Poor 0.48 (0.24–0.95)† 0.0341 GSE22155 Upper 25%
      0.69 (0.50–0.95)† 0.0235 TCGA Upper 25%
BCL6 [41] 88 6-year OS Poor 0.57 (0.40–0.80)† 0.0011 TCGA Upper 25%
FXYD5 [42] 115 OS Poor 3.10 (1.24–7.76)† 0.0159 GSE19234 Upper 25%
DDIT3 [43] 106 OS Good 5.74 (2.18–15.13)† 0.0004 GSE98394 Upper 25%
MCAT [44] 1270 DFI and OS Poor 5.75 (1.26–26.10)† 0.0236 GSE22155 Upper 25%
      4.51 (1.72–11.82)† 0.0021 GSE98394 Upper 25%
CTNNB1 [45] 202 DSS Good 1.55 (1.02–2.37)‡ 0.0412 GSE65904 Upper 25%
      1.75 (1.15–2.67)‡ 0.0088 GSE65904 Upper 25%
AKT1 [46] 222 5-year DSS or OS Poor 6.41 (2.39–17.23)† 0.0002 GSE98394 Upper 25%
      1.53 (1.13–2.06)† 0.0056 TCGA Upper 25%
RUNX3 [47] 421 5-year OS Good 3.75 (1.36–10.33)† 0.0107 GSE50509 Upper 25%
    5-year DSS   1.81 (1.18–2.76)‡ 0.0062 GSE65904 Upper 25%
BBC3 [48] 158 5-year DSS or OS Poor 3.62 (1.38–9.52)† 0.0092 GSE98394 Upper 25%
MMP2 [49] 157 DSS and RFS Poor 1.41 (1.06–1.89)‡ 0.0197 TCGA Upper 50%
SPP1 [50] 345 RFS Poor 9.42 (3.46–25.67)† < 0.0001 GSE98394 Upper 25%
TNC [51] 98 DFS Poor 1.54 (1.01–2.34)‡ 0.0434 GSE65904 Upper 25%
CCNA2 [52] 245 RFS Poor 2.23 (1.02–4.88)† 0.0437 GSE50509 Upper 25%
RGS1 [53] 40 DSS Poor 2.74 (1.03–7.24)† 0.0425 GSE98394 Upper 25%
      3.24 (1.31–8.00)† 0.0110 GSE19234 Upper 25%
      2.66 (1.07–6.65)† 0.0357 GSE19234 Upper 25%
SPARC [54] 112 DFS Poor 2.78 (1.21–6.34)† 0.0154 GSE50509 Upper 25%
CXCR4 [55] 71 DFS and OS Poor 0.70 (0.51–0.97)† 0.0315 TCGA Upper 25%
RBM3 [56] 246 OS Good NS NS – –
EPAS1 [57] 46 DSS Poor 3.51 (1.56–7.91)† 0.0024 GSE50509 Upper 25%
  1. NS not significance, RFS recurrence-free survival, DFS disease-specific survival, DFI disease-free interval, DMFI distant metastasis-free interval
  2. †,‡HR (95%CI) and Log-rank P value of overall survival (OS) and disease-specific survival (DSS)
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us